AP2B1 and Parkinson disease: Markers of synaptic dysfunction are increased in the CSF28 of patients with Alzheimer’s disease, while the levels of many markers (e.g. AP2B1, LAMP2, Secretogranin-2) were decreased in a cross-sectional PD cohort33.